Allergen chip in molecular diagnostic: from cohort analysis to personalized patient care

Le résumé fourni par la source

Background. The allergic diseases are growing everywhere. The exact diagnosis of allergens becomes more and more critical because it significantly affects the further treatment of the patient, including the question about using the allergen-specific immunotherapy. There are several laboratory and instrumental allergic tests among which the skin tests are the most available. Despite its low cost, this method is characterized by a large percentage of false-positive and, more importantly, false-negative results. In addition, the allergens that can be detected by skin tests are limited.Aim. To conduct a comparative analysis of the effectiveness and diagnostic accuracy of allergen chips from different manufacturers and to evaluate their applicability in the molecular diagnosis of allergic diseases.Results. ImmunoCAP ISAC and Allergy Explorer (ALEX) tests are gradually occupying their niche in the molecular diagnosis of allergic diseases. Both methods have their benefits and disadvantages. The high cost and difficulties in supplying foreign materials sharply limit the widespread use of allergy profiles in Russia. On the other hand, personalized medicine requires doctors to have a patient-centered care, which is completed using existing diagnostic tools. The allergy panels for various regions of Russia can solve this problem. Identifying the most common clinically significant molecules in each region will enable more accurate diagnosis of allergies and personalized patient treatment. This will improve medical care quality and increase therapy effectiveness.Conclusion. Developing and implementing new diagnostic methods and creating allergen panels optimal for each region are important steps towards improving the diagnosis and treatment of allergic diseases. These measures will help clinicians more accurately identify relevant allergens and develop individual treatment plans for each patient, ultimately leading to better public health and lower economic costs for treating allergies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.